Libtayo® (cemiplimab) Approved in the European Union as First and Only Immunotherapy for Adjuvant Treatment of Cutaneous Squamous Cell Carcinoma (CSCC) with High Risk of ...

Approval based on results of landmark Phase 3 C-POST trial that show Libtayo is first immunotherapy to significantly improve disease-free ...

‘It would be cheaper if I died:’ Cancer patients are battling insurance companies for their lives

EXCLUSIVE: Cancer patients, oncologists and advocates tell Rhian Lubin why the US health insurance system needs urgent reform, and is risking the lives of Americans fighting the disease ...

Serious pregnancy complications 'dramatically reduced' in HPV-vaccinated women

Pregnant women who were vaccinated against human papillomavirus (HPV) at school are less likely to experience serious ...
India Today on MSN

Pain isn't normal: How some gynae symptoms could signal cancer

Women often dismiss gynaecological pain as normal, risking late cancer diagnosis. But any kind of discomfort is not "not ...